WHO Issues Warning Over Acute Shortage of Obesity Injections
Less than one in 10 patients who could benefit from weight-loss injections including Wegovy are able to get them, states the World Health Organization as it issues its inaugural recommendations on the drugs.
With more than one billion people worldwide now living with obesity, it is urging increased and just access to this class of drugs.
Based on estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidelines acknowledges that obesity is a chronic disease that can be treated with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major obstacles to broad availability to the treatments that can aid individuals in losing substantial body mass, explains the body.
Skinny Jab Shortage
Even under the current best projected scenario, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of eligible patients, according to the WHO.
The advice encourages countries and companies to widen access, via measures including patent sharing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so individuals eat less.
Individuals typically see weight reduction within a few weeks of beginning the once-weekly jabs.
Studies indicates users may regain a significant portion after a year of discontinuing the medication, because their usual hunger resume.
Being above a healthy weight elevates your likelihood for contracting health problems, like diabetes, heart disease, stroke, and specific cancers.
Obesity affects people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
